VA Chief Touts Progress on Psychedelic Therapy for Veterans
Photo by RDNE Stock project via Pexels.
Doug Collins didn't mince words after stepping out of a roundtable with veterans at American Legion Post 273 in Madeira Beach, Florida on July 30, 2026. Flanked by Rep. Anna Paulina Luna, the VA Secretary told reporters the agency has abandoned its old posture of watching psychedelic research from the sidelines. The department, he said, is now positioning itself as a serious player in developing treatments for the mental health conditions that have quietly devastated the veteran community for decades.
That shift didn't happen in a vacuum. It's the visible surface of a much larger federal push, one anchored by President Trump's Executive Order 14401, which directs agencies to accelerate research into psychedelic-assisted therapies for PTSD and suicide prevention among veterans. Collins' comments in Pinellas County read less like a standalone announcement and more like a status update on a policy machine that's been running for over a year -- one now producing trial data, funding commitments, and interagency agreements that didn't exist before this administration made veteran mental health a stated priority.
What Collins Said in Florida
Photo by Charles Criscuolo via Pexels.
The setting mattered as much as the message. American Legion posts have hosted plenty of political photo ops over the years, but this one, tucked into Pinellas County on Florida's Gulf Coast, put Collins in a room with veterans who've likely tried the standard VA treatment menu -- SSRIs, talk therapy, maybe exposure therapy for PTSD -- without full relief. That's the audience Collins was speaking to when he said the department is moving from a wait-and-see approach to being more cutting-edge in how it diagnoses and treats veterans.
Inside the VA's 20 Active Psychedelic Trials
In a VA psilocybin study, 9 of 12 veterans no longer met PTSD diagnostic criteria one month after treatment, while only 3 still did—suggesting a strong potential benefit of the therapy.
Behind the rhetoric, there's an actual research portfolio taking shape. The VA currently backs 20 active clinical trials examining psychedelic-assisted therapies, supported by more than $23 million in external funding flowing into academic and clinical partners. That's a real infrastructure buildout, not a talking point.
The Executive Order Driving It All
Photo by Thuan Vo via Pexels.
Collins' progress report doesn't exist in isolation -- it's the department checking in on a mandate that came from the top. On April 18, 2026, President Trump signed Executive Order 14401, titled Accelerating Medical Treatments for Serious Mental Conditions, and it reads like a direct instruction to move faster on exactly the compounds Collins was discussing in Florida.
VA and HHS Formalize Their Partnership
Photo by Werner Pfennig via Pexels.
If the executive order set the destination, the memorandum of understanding signed in mid-July 2026 at VA headquarters is the roadmap for getting there. HHS Secretary Robert F. Kennedy Jr. and Collins put their names on an agreement designed to turn the executive order's broad directives into operational machinery connecting two massive federal bureaucracies.
Strip away the press-conference framing and what's actually changed is fairly concrete: the federal government has gone from quietly monitoring psychedelic research to actively funding it, fast-tracking its review, and building the bureaucratic pipes to move results from lab to clinic faster than the normal FDA timeline would allow. That's a genuine shift in posture, and Collins deserves credit for saying it out loud rather than letting it stay buried in agency budget documents.
But every promising number cited so far -- the 9 of 12 veterans in the Ohio psilocybin study, the 80 participants enrolling in the MDMA trial, the ibogaine interest Collins keeps fielding from veterans -- comes from small, early-stage research, not approved medicine sitting on a pharmacy shelf. Whether any of these compounds reach the broader veteran population still hinges entirely on FDA approval timelines, and Collins himself has been clear that ibogaine, in particular, still has to clear that bar before U.S. trials can even expand in scale.
Worth remembering too: outside these specific federally sanctioned research protocols, psychedelics remain Schedule I controlled substances under federal law, and state-level rules on related research, decriminalization, or supervised use vary widely and keep shifting. Anyone following this story with more than passing curiosity should check current federal and state law before assuming any of this translates into legal access -- because right now, it doesn't.
